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Aims Coronary microvascular dysfunction and/or vasospasm are potential causes of ischaemia in patients with no ob-
structive coronary artery disease (INOCA). We tested the hypothesis that these patients also have functional
abnormalities in peripheral small arteries.
...................................................................................................................................................................................................
Methods
and results
Patients were prospectively enrolled and categorised as having microvascular angina (MVA), vasospastic angina
(VSA) or normal control based on invasive coronary artery function tests incorporating probes of endothelial and
endothelial-independent function (acetylcholine and adenosine). Gluteal biopsies of subcutaneous fat were per-
formed in 81 subjects (62 years, 69% female, 59 MVA, 11 VSA, and 11 controls). Resistance arteries were dissected
enabling study using wire myography. Maximum relaxation to ACh (endothelial function) was reduced in MVA vs.
controls [median 77.6 vs. 98.7%; 95% confidence interval (CI) of difference 2.3–38%; P= 0.0047]. Endothelium-
independent relaxation [sodium nitroprusside (SNP)] was similar between all groups. The maximum contractile re-
sponse to endothelin-1 (ET-1) was greater in MVA (median 121%) vs. controls (100%; 95% CI of median difference
4.7–45%, P= 0.015). Response to the thromboxane agonist, U46619, was also greater in MVA (143%) vs. controls
(109%; 95% CI of difference 13–57%, P= 0.003). Patients with VSA had similar abnormal patterns of peripheral vas-
cular reactivity including reduced maximum relaxation to ACh (median 79.0% vs. 98.7%; P= 0.03) and increased
response to constrictor agonists including ET-1 (median 125% vs. 100%; P= 0.02). In all groups, resistance arteries
were 50-fold more sensitive to the constrictor effects of ET-1 compared with U46619.
...................................................................................................................................................................................................
Conclusions Systemic microvascular abnormalities are common in patients with MVA and VSA. These mechanisms may involve
ET-1 and were characterized by endothelial dysfunction and enhanced vasoconstriction.
...................................................................................................................................................................................................
Clinical trial
registration
ClinicalTrials.gov registration is NCT03193294.
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Introduction
Coronary microvascular dysfunction and/or vasospasm are potential
causes of ischaemia in patients with no obstructive coronary artery
disease (INOCA).1 Patients with INOCA have unmet clinical needs
with high morbidity, impaired quality of life, and health resource
utilization.2,3 Relevant tests to determine the presence of coronary
microvascular dysfunction are rarely performed during invasive cor-
onary angiography, but they may provide the diagnosis (Figure 1A).
The 2013 European Society of Cardiology (ESC) guidelines on the
management of stable coronary artery disease (CAD) were notable
as the first international practice guidelines to address the diagnosis
and management of functional coronary disorders.4
Importantly, microvascular disease may be a multi-system entity
with links between coronary microvascular dysfunction and small
vessel disease of the kidney,5 retina,6 and cerebral white matter.7
Indeed, systemic endothelial impairment has been suggested as a key
mediator in the pathogenesis of coronary microvascular dys-
function.8,9 The technique of wire myography has been used to inves-
tigate peripheral vascular dysfunction in conditions such as
hypertension,10 heart failure,11 and renal failure12 (Figure 1B). We
hypothesised that small vessel damage in the heart may be a systemic
phenomenon and that patients have generalized endothelial dysfunc-
tion leading to abnormal vascular reactivity assessed using wire myog-
raphy. To test this hypothesis, we designed a case–control study to
investigate peripheral small artery changes in two distinct groups of
INOCA—those with microvascular angina (MVA) and those with
vasospastic angina (VSA). Our aim was to compare peripheral endo-
thelial function and vascular reactivity in these two groups with
matched control subjects (chest pain but normal invasive assessment
of coronary microvascular function).
Methods
Study population
We screened elective adult referrals to two large cardiac catheterization
laboratories with clinical suspicion of significant coronary artery disease
based on the presence of angina. Patients were prospectively recruited
from the larger British Heart Foundation Coronary Microvascular Angina
(CorMicA) study which is a randomized controlled trial evaluating the ef-
fect of diagnostic strategy and linked therapy on symptoms and quality of
life in INOCA.13 The Rose–Angina questionnaire was administered on the
day of the angiogram and only patients with definite or possible angina
were eligible for the study.14 Exclusion criteria included a non-coronary in-
dication for invasive angiography e.g. valve disease, severe renal dysfunction
(GFR <30 mL/min), inability to give informed consent, and obstructive cor-
onary disease on coronary angiography [>_50% diameter stenosis and/or
fractional flow reserve (FFR) <_0.80]. All coronary vasodilating drugs were
discontinued at least 24 h before coronary artery function testing.
Definitions: microvascular angina,
vasospastic angina, and control subject
We defined MVA according to the COVADIS diagnostic criteria: stable
angina,14 unobstructed coronary arteries and proven coronary micro-
vascular dysfunction (Table 1). The CorMicA study design paper describes
the coronary artery function testing procedure.13 A total of 11 control
subjects were recruited: 9 from the CorMicA study (NCT03193294) and
2 from a contemporaneous related study (CorCTCA: NCT03477890).
Control subjects had stable chest pain syndromes investigated with the
same diagnostic protocols but coronary microvascular dysfunction was
not found during invasive interrogation. Coronary microvascular dysfunc-
tion during acetylcholine (ACh) (microvascular spasm) was defined as re-
production of angina, ischaemic electrocardiogram (ECG) shifts, but no
epicardial spasm during ACh testing.27 Patients without coronary micro-
vascular dysfunction but with significant epicardial vasoconstriction
(>_90%) during ACh testing along with (i) reproduction of the usual chest
pain and (ii) ischaemic ECG changes, were diagnosed with VSA according
to the COVADIS criteria and formed a comparator group.15
Coronary artery function testing
In brief, we measured coronary flow reserve (CFR) and the index
of microcirculatory resistance (IMR) using thermodilution as
previously described.16,17 An intravenous infusion of adenosine
(140 lgkg-1min-1) was administered via a large peripheral vein to in-
duce steady-state maximal hyperaemia. Increased IMR (>_25) was rep-
resentative of microvascular dysfunction.18 Coronary flow reserve
was calculated using thermodilution as resting mean transit time div-
ided by hyperaemic mean transit time19 (abnormal CFR is defined
as <2.0).20 Fractional flow reserve was calculated by the ratio of mean
distal coronary pressure to mean aortic pressure at maximal hyper-
aemia—abnormal FFR is defined as <_0.80.
Coronary vasoreactivity testing
The target vessel was the left anterior descending coronary artery. If tech-
nical factors, e.g. vessel tortuosity, precluded assessment of this artery then
the left circumflex or right coronary artery was selected. We assessed
endothelium-dependent coronary vasomotor function using intra-coronary
infusions of ACh via the guiding catheter at concentrations of 0.182, 1.82,
and 18.2mg/mL (10-6, 10-5, and 10-4mol/L, respectively) at 1mL/min for
2min via a mechanical infusion pump.21 We then performed provocation
testing for epicardial coronary artery spasm using a 100lg bolus of ACh
(5.5mL of 10-4mol/L over 20 s—reduced to 50lg for the right coronary
artery).
Preparation of small resistance arteries
Vessels were dissected from a gluteal skin fat biopsy (approximately
3 2 2 cm) within 4 weeks of coronary angiography. Vasoactive medi-
cations were withheld for at least 24 hours prior to the surgical biopsy.
Small resistance arterioles (normalized diameter <400lm) were studied
in a Mulvany-Halpern 4-channel wire myograph (Danish Myotech,
Aarhus, Denmark) with isometric tension recordings made as previously
described.22
Experimental Protocol
After a standard normalization and start-up protocol involving repeated
washes with high potassium chloride solution (62.5 mM), the arterioles
were pre-constricted with thromboxane-A2 analogue (U46619; 0.1lM).
Previous work on human resistance arteries support its application in
myography due to its consistent vasoconstriction with a steady plateau
from which to assess arteriolar relaxation. Blood vessels with no
responses were discarded. We averaged the relaxation response to each
incremental concentration of acetycholine (ACh; 1nM-3lM) in multiple
arterioles in each subject. This served to increase accuracy by levelling
out the regional heterogeneity of endothelial function in vivo.23,24 We
then performed separate parallel experiments with cumulative concen-
tration response curves (CCRCs) to the vasoconstrictors endothelin-1
(ET-1; 1pM-1lM) and thromboxane-A2 analogue (U46619; 0.1nM-
3lM). After performing the U46619 CCRC, a vessel washout was
performed and further preconstruction to U46619 allowed us to
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Figure 1 (A) Illustrative case of microvascular angina. (B) Gluteal biopsy procedure, dissection of resistance artery, and myography workstation.
(A) A 43-year-old female smoker with family history of early cardiovascular disease was referred for invasive angiography with 12 months of typical
angina and positive stress ECG. Recruited into British Heart Foundation CorMicA study with findings of non-obstructive atheroma in the left anterior
descending coronary artery. Pressure wire assessment confirmed profoundly reduced coronary flow reserve (1.3) but non-obstructive physiology
(fractional flow reserve 0.86) and normal index of microvascular resistance with adenosine (index of microcirculatory resistance 18). Acetylcholine
testing confirmed microvascular spasm to acetylcholine (reproduction of typical angina, ST segment deviation and <90% epicardial vasoconstriction
to acetylcholine. (B) Surgical gluteal skin fat biopsy with dissection of resistance artery under light microscopy. Peripheral resistance arteries were
harvested and set-up for our wire myography protocol. The myography tracing shows a cumulative concentration-response curve to dilator agonist
acetylcholine. We averaged the relaxation at each concentration compared to baseline confirming reduced maximal relaxation to this probe of endo-
thelial function. Overall this lady was diagnosed with microvascular angina (typical angina, proven coronary microvascular dysfunction) with evidence
of widespread peripheral endothelial dysfunction.
4088 T.J. Ford et al.
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.examine the effects of endothelial independent vasodilator, sodium nitro-
prusside (SNP; 0.1nM-3lM). Due to the irreversible nature of ET-1 re-
ceptor binding, arterioles subjected to ET-1 CCRC were not used for
further experiments. Cumulative concentrationresponse curves were fit-
ted using four-parameter, non-linear regression curve fitting in Prism 7.0
(GraphPad Inc, La Jolla, CA, USA). Maximum efficacy (Emax) for vasocon-
strictors was expressed as a percentage of the mean response of the con-
traction to 62.5mM potassium chloride solution. For relaxation data, the
maximum response (Emax) to ACh was expressed as percentage relax-
ation after preconstruction with thromboxane analogue (U46619;
0.1lM). Sensitivity of the arterioles to each compound was expressed as
the pEC50 (constrictors) or pIC50 (inhibitors) derived from the CCRC.
Prism 7.0 The pEC50 value represents the minus log concentration
required to produce 50% of the maximum response. Similarly, pIC50 is
the -log of concentration required to inhibit 50% of the maximum re-
sponse. Higher numbers indicate more potency (less concentration
required to achieve the median response).
Statistical analysis
The study population analysed comprised all of the participants who under-
went a biopsy and no patients were excluded even if no viable vessels were
dissected. The primary endpoint of this study was the difference in max-
imum relaxation induced by ACh (ACh Emax) between two groups: MVA
and control subjects. Sample size calculations were based on this measure.
Using an allocation ratio of 5:1 (MVA:controls), we calculated that a sample
size of 52 patients and 10 controls would have 80% power to detect
between group difference in ACh Emax of 10% at the 5% significance level.
A minimum sample size of 62 subjects was estimated using G*Power 3.1
(University of Melbourne, Parkville, Victoria, Australia). This calculation
used the Mann–Whitney U test reflecting small sample size and likelihood
of non-parametric distribution.12 A secondary analysis was performed to
evaluate differences in potency and efficacy of dilator and constrictor
agonists between all three groups. The Kruskal–Wallis test was used to
evaluate this with an adjustment for multiple comparisons (controlling the
false discovery rate).
Results are reported as mean (± standard deviation) for parametric
data and median (25th and 75th percentile) for data that were not normal-
ly distributed. The Fisher’s exact test or the v2 test was used to assess for
differences between categorical variables. One-way analysis of variance
was used to assess for differences between means of continuous normally
distributed variables across three groups (adjusted for multiple compari-
sons). We applied the Shapiro–Wilk normality test to establish whether
the data followed a parametric distribution. Best-fit cumulative concentra-
tion curves (CCRCs) were compared with the extra sum-of-squares
F test. We performed two-tailed analysis and considered a P-value <0.05
to be significant. Statistical analyses were performed with Prism 7.0
(GraphPad, La Jolla, CA, USA) and SPSS 24.0 (SPSS, Chicago, IL, USA).
Results
From December 2017—June 2018, 81 subjects gave informed consent
and underwent clinically-indicated invasive coronary angiography
coupled with guidewire-based measurements of coronary artery func-
tion and vasoreactivity testing. A gluteal skin fat biopsy was then
obtained within 4 weeks of the angiogram. The mean age of the MVA
patients was 63 years which was similar to the VSA and control sub-
jects. Overall, the characteristics of the patients including demograph-
ics, risk factors, and treatment were similar between the groups
(Table 2). Non-obstructive epicardial CAD severity, assessed using
Gensini score25 and FFR, did not differ between the groups (P= 0.15).
All 59 MVA patients had demonstrable evidence of coronary micro-
vascular dysfunction including 50 (85%) with abnormal CFR and/or
....................................................................................................................................................................................................................
Table 1 Definitions of abnormalities in coronary artery function
Disorder of coronary artery function
CMD " Microvascular resistance
(IMR >_25)
The IMR represents a quantitative metric of microvascular function independent of resting
haemodynamics
IMR = distal coronary pressure * transit time (average time for 3 saline bolus runs at hyperaemia)
# Coronary vasorelaxation
(CFR <2.0)
CFR by thermodilution. A CFR<2.0 reflects the failure to increase coronary flow above two times
the resting flow in response to a hyperaemic stimulus
Microvascular spasm Reproduction of usual angina during intracoronary infusion of ACh with ischaemic ST-segment
changes but no significant epicardial coronary constriction (<90% reduction in epicardial coronary
diameter). Represents inappropriate susceptibility to microvascular constriction
VSA Epicardial spasm Epicardial coronary artery spasm is defined as
• >_90% reduction in coronary diameter following intracoronary administration of ACh (100 mg)
• Reproduction of usual symptoms
• ST segment deviation on the ECG
Non-cardiac
(control)
Nil Exclusion of diffuse or obstructive epicardial coronary disease (FFR >0.8)
Normal invasive metrics of coronary artery function:
• CFR >_2.0
• IMR <25
• Negative provocation testing (ACh)
ACh, acetylcholine; CFR, coronary flow reserve; CMD, coronary microvascular dysfunction; FFR, fractional flow reserve; IMR, index of microcirculatory resistance; INOCA,
ischaemia and non-obstructive coronary artery disease; MVA, microvascular angina; VSA, vasospastic angina.
Systemic microvascular dysfunction in MVA and VSA 4089
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IMR, 23 (39%) with evidence of microvascular spasm to ACh and 14
(24%) with abnormalities to both adenosine and ACh. Coronary flow
reserve was reduced in MVA (2.4± 1.1) vs. VSA (3.6± 2.2) and control
subjects (3.7± 1.1; P= 0.001). Coronary microvascular resistance was
greater in MVA (mean IMR 28.2± 16.3) compared with VSA
(15.8± 1.6) and control subjects controls (16.6± 6; P= 0.005).
In total, 81 biopsies were performed (59 MVA, 11 VSA and 11
controls). Three surgical biopsies had no functional small resistance
arteries (all MVA patients). The normalized internal diameters of re-
sistance arteries did not differ between MVA, VSA, and control sub-
jects (mean diameter 345 vs. 332 vs. 315mm, P= 0.43; Table 3).
Additional information on vessels including length and number of
viable vessels is demonstrated in Table 4.
Responses to dilator agonists
Acetylcholine and SNP evoked concentration-dependent relaxations in
preconstructed resistance arteries from all groups. For the primary
study endpoint, the maximum relaxation to ACh was significantly lower
in patients with MVA compared with controls [median 77.6% vs. 98.7%;
95% confidence interval (CI) of difference in medians 2–38%, Mann-
Whitney U = 106, P= 0.0047; Table 3 and Figure 2A]. The maximum re-
laxation to ACh was also lower in patients with VSA compared with
controls (median 79.0 vs. 98.7%; P= 0.031; Table 3 and Figure 2B). The
maximum relaxation to ACh did not differ between patients with MVA
and VSA (P= 0.967, Figures 2B and 3A). Maximum relaxation to the
endothelium-independent dilator, SNP, was similar in small resistance
arteries from MVA patients compared with controls (97 vs. 98%; 95%
....................................................................................................................................................................................................................
Table 2 Baseline demographics and invasive coronary artery function
MVA (n559) VSA (n5 11) Control (n5 11) P-value
Age (years) 63 (±10.2) 57 (±11) 61 (±8) 0.19
Female gender 40 (68) 8 (73) 8 (73) 0.91
Diabetes 9 (15) 1 (9) 1 (9) 0.77
Hypertension 42 (71) 6 (55) 7 (64) 0.74
Previous MI 12 (20) 0 (0) 0 (0) 0.07
Current smoker 10 (17) 1 (9) 1 (9) 0.68
BMI (kg/m2) 30 (±6.8) 25.6 (±8.9) 32.4 (±7.5) 0.08
Pulse (min) 71 (±13) 71 (±14) 69 (±13) 0.88
Systolic blood pressure (mmHg) 138 (±22) 133 (±25) 138 (±17) 0.72
Diastolic blood pressure (mmHg) 72 (±12) 73 (±16) 74 (±12) 0.84
Medications
ACE-I 24 (41) 5 (45) 4 (36) 0.91
Beta blocker 40 (68) 7 (64) 6 (55) 0.69
CCB 20 (34) 5 (45) 4 (36) 0.76
Statin 49 (83) 10 (91) 7 (64) 0.22
Cholesterol (mmol/L) 3.5 (±1.0) 3.3 (±1.1) 4.2 (±1.7) 0.13
Glucose (mmol/L) 4.9 (±1.8) 4.3 (±1.2) 4.5 (±0.9) 0.42
hsCRP (mg/L)a 3.5 (±5.2) 1.3 (±1.0) 4.9 (±10.4) 0.39
Coronary angiography and invasive coronary physiology
Angiographically normal 28 (47) 8 (73) 7 (64) 0.23
Gensini score 3.2 (±2.2) 1.6 (±2.2) 1.4 (±2.1) 0.15
LVEDP (mmHg) 10 (±4) 8 (±2) 8 (±2) 0.44
FFR 0.88 (±0.05) 0.88 (±0.05) 0.89 (±0.04) 0.77
Coronary microvascular dysfunction 59 (100) 0 (0) 0 (0) <0.001
CFR and/or IMR 50 (85) 0 (0) 0 (0) <0.001
IMR >_25 31 (53) 0 (0) 0 (0) <0.001
CFR <2.0 32 (55) 0 (0) 0 (0) <0.001
CFR <2.5 41 (71) 3 (27) 1 (9) <0.001
CMD to ACh 23 (39) 0 (0) 0 (0) 0.003
Both ACh and CFR/IMR 14 (24) 0 (0) 0 (0) 0.043
CFR 2.4 (±1.1) 3.6 (±2.2) 3.7 (±1.1) 0.001
IMR 28.2 (±16.3) 15.8 (±1.6) 16.6 (±6) 0.005
Data are represented as mean (±SD) and number (%). Includes all patients in intention-to-treat analysis. Significance determined as comparison between three groups by one-
way analysis of variance or Pearson v2 test for categorical variables adjusted using the Bonferroni correction for multiple comparisons.
ACE-I, angiotensin converting enzyme inhibitor; ACh, acetylcholine; BMI, body mass index; CCB, calcium channel blocker; CFR, coronary flow reserve; CMD, coronary micro-
vascular dysfunction; CRP, C-reactive protein; FFR, fractional flow reserve; hsCRP, high sensitivity C-reactive protein; IMR, index of microcirculatory resistance; LVEDP, left ven-
tricular end-diastolic pressure; MI, myocardial infarction.
ahsCRP results available in only 8 controls, 10 VSA, and 47 MVA.
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Table 3 Maximum responses and sensitivities to dilator and constrictor agonists in resistance arteries from patients
with microvascular angina, vasospastic angina, and control subjects with normal coronary function
MVA (n559) VSA (n5 11) Control (n5 11)
P-valuea P-valuea
Normalized vessel diameter (mm)b 345 (±95) 0.34 332 (±85) 0.66 315 (±96)
ACh
N 48 9 10
Emax (%) 77.6 <0.01 79.0 0.03 98.7
pIC50 7.1 0.49 7.1 0.73 7.3
SNP
N 49 10 10
Emax (%) 97 0.99 99 0.99 98
pIC50 7.0 0.50 6.5 0.30 7.5
ET-1
N 54 11 9
Emax (%) 121 0.03 125 0.02 100
pEC50 9.6 0.17 9.5 0.49 9.3
U44619
N 54 10 11
Emax (%) 143 0.01 141 0.04 109
pEC50 8.0 0.02 7.5 0.67 7.50
Data for diameter are represented as mean (±SD). Potency is expressed as the -log concentration required to produce 50% of the maximum response (IC50 for antagonists,
EC50 for agonists).
ACh, acetylcholine; Emax, maximum efficacy for constrictor agonists is expressed in terms of percentage of maximum response to KPSS solution, for dilator agonists Emax refers
to maximum relaxation after preconstruction with U46619; SNP, sodium nitroprusside.
aEfficacy and potency were not significantly different between the MVA and VSA groups for any of the agonists studied. P-value represents two-tailed comparison of median
from each group with median of the control group using Kruskal-Wallis test (adjusting for multiple comparisons using the false discovery rate)
bL0 = 90% of the normalized vessel diameter. P-value represents an unpaired t-test comparing vessel diameter of MVA versus control and VSA versus control.
....................................................................................................................................................................................................................
Table 4 Vessel information
MVA (n5 59) VSA (n511) Controls (n5 11) P-value
N with viable vessels 56 (95%) 11 (100%) 11 (100%) 0.56
Vessels per subject 6.2 (1.9) 6.2 (±2.4) 5.7 (±2.3) 0.81
Length (mm) 1.85 (±0.1) 1.86 (±0.1) 1.82 (±0.1) 0.66
Acetylcholine
Patients 48 (84%) 9 (82%) 10 (91%) 0.33
Vessels 176 32 22
SNP
Patients 49 (97%) 10 (91%) 10 (91%) 0.32
Vessels 58 16 15
U46619
Patients 54 (93%) 10 (91%) 11 (100%) 0.84
Vessels 75 16 15
Endothelin-1
Patients 54 (94%) 11 (100%) 9 (82%) 0.14
Vessels 54 12 10
Patients = number of patients in whom a complete concentration-response curve was obtained for the agonist. Vessels refer to the number of vessels used in the group to aver-
age the response. Data are mean (±SD) with comparison by one-way analysis of variance.
Systemic microvascular dysfunction in MVA and VSA 4091
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CI of difference in medians -3.3 to 4.5%, P= 0.962; Table 3 and
Figure 3B).
Responses to constrictor agonists
All arteries responded in a concentration-dependent manner to both
endothelin-1 (ET-1) and U46619. In all subjects, blood vessels were
50-fold more sensitive to the constrictor effects of ET-1 compared
with the thromboxane agonist U46619 (median ET-1 pIC50 ET-1 9.6 vs.
7.9; 95% CI of median difference in pIC50 1.4–1.9; Mann-Whitney
U = 247, P< 0.001). Importantly, the maximum constrictor response to
ET-1 was greater in MVA compared with the control group (121% vs.
100%; P= 0.03; Figure 4A). The maximum response to U46619 was also
greater in MVA (143% vs. 109%; P= 0.01; Table 3 and Figure 4B). The
VSA group had similar patterns of increased vasoconstriction to both
ET-1 (median 125% vs. 100%; P= 0.02) and U46619 (median 141 vs.
109%; P= 0.04). These were not significantly different from the MVA
subjects (Table 3 and Figure 4). The key findings of the study are
summarized in the Take home figure.
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Figure 2 (A) Primary endpoint: maximum vasorelaxation to
acetylcholine (Emax). (B) Comparison of maximum relaxation to
acetylcholine between the three groups. (A) Ranks: the Mann–
Whitney U test ranking of microvascular angina vs. control subjects
confirming significantly lower maximum vasorelaxation in response
to acetylcholine between microvascular angina patients and control
subject (median 77.6 vs. 98.7%; 95% confidence interval of difference
between medians 2.3–38%; P = 0.0047). (B) Comparison of three
groups confirming both microvascular angina subjects (blue circle;
acetylcholine Emax 77.6%, n = 48) and vasospastic angina subjects
(red triangle; acetylcholine Emax 79%, n = 9) had reduced maximum
vasorelaxation to acetylcholine than vs. control subjects (—white
circle, Emax 98.7%, n = 10). Significance P < 0.01 and P = 0.03, re-
spectively using the Kruskal–Wallis test (adjusted for multiple com-
parisons by controlling the false discovery rate). Each measure
represents mean ± 95% confidence intervals for mean in shaded
contours from CCRC best-fit. There were no significant differences
in maximum relaxation to acetylcholine between microvascular an-
gina and vasospastic angina subjects (P = 0.96).
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Figure 3 Cumulative concentration-response curves to dilator
agonists. (A) Endothelial function assessed by acetylcholine showing
impairment in vasorelaxation in both microvascular angina subjects
(blue circle; acetylcholine Emax 77.6%, n = 48; P < 0.01) and vaso-
spastic angina subjects (red triangle; acetylcholine Emax 79%, n = 9;
P = 0.03) vs. control subjects (—white circle, Emax 98.7%, n = 10).
No difference in acetylcholine Emax between microvascular angina
and vasospastic angina subjects (P = 0.967). Comparison of
CCRC fit, P < 0.001. (B) No difference in vasorelaxation to
endothelial independent probe, sodium nitroprusside between
microvascular angina patients (blue circle, sodium nitroprusside
Emax 97%, n = 49), vasospastic angina subjects (red triangle; acetyl-
choline Emax 99%; n = 10) and control subjects (—white circle,
Emax 98%, n = 10; P = 0.99). Each measure represents mean ± 95%
confidence intervals for mean in shaded contours from CCRC best-
fit. No difference in response to sodium nitroprusside between the
groups, P = 0.4914.
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Safety of biopsy procedure
No serious adverse events occurred following the gluteal biopsy.
There were 5 (6.2%) cases of minor wound dehiscence post procedure
without clinically significant wound infection. Wound healing occurred
by secondary intention in all cases without additional treatment.
Discussion
We have shown altered function of peripheral small arteries in
patients with INOCA compared with control subjects. Specifically,
both MVA and VSA patients had peripheral microvascular abnormal-
ities characterized by reduced maximum relaxation to ACh (in keep-
ing with endothelial dysfunction) and increased responses to
vasoconstrictor stimuli. Vasoconstriction in response to ET-1 and the
thromboxane agonist U46619 was greater in MVA and VSA patients.
Overall, our results stimulate the provocative concept that patients
with MVA or VSA are at risk of developing systemic small vessel dis-
ease. Our study helps explain the associations between coronary
microvascular dysfunction and small vessel disease in other organs,
such as the brain and kidney.26
To our knowledge, this is the first study to prospectively investi-
gate patients with INOCA and objective invasive evidence of coron-
ary microvascular function using wire myography to assess peripheral
vascular function. These assessments were temporally approximated
within a 4 week period. Furthermore, a control group of subjects
with normal coronary microvascular function who underwent the
same interventional diagnostic procedures were also included. This
protocol included reference invasive coronary testing based on ESC4
and COVADIS27 diagnostic criteria for disorders of coronary artery
function. We used validated questionnaires to classify angina symp-
toms as an eligibility criterion to avoid inclusion of patients with non-
cardiac chest pain.14 All patients had non-obstructive coronary artery
disease as determined by an FFR value >0.80. Patients were then
diagnosed with either MVA or VSA based on the presence coronary
microvascular dysfunction or significant epicardial constriction during
provocation testing. The control group (comprising patients referred
with chest pain proven not to have any abnormality in coronary ar-
tery function) was considered to be a more appropriate control
population than volunteers without classification of coronary vascu-
lar function.
Wire myography is a reference technique for in vitro research
of small resistance arteries and is well established in our labora-
tory. This method enables vascular mechanisms to be specifically
investigated, which otherwise would not be possible in vivo. Our
findings extend prior studies that identified abnormalities in per-
ipheral vascular function in patients with both MVA28 and VSA.29
Microvascular angina is a disorder of coronary microvessels
(<_400lm)30 whereas VSA is a disorder of conduit arteries,31 and
thus it is somewhat surprising that both groups have reduced re-
laxation to ACh compared with controls. Systemic endothelial
dysfunction may simply be a secondary manifestation of coronary
vascular dysfunction. Alternatively, it may be a primary feature
reflecting underlying pathophysiology in both conditions. Our
study was not powered to detect a difference between ACh
Emax between MVA and VSA, so we cannot draw definitive con-
clusions about comparative endothelial function between the
MVA and VSA groups. It would be expected that MVA patients
would have reduced endothelial function compared with VSA
patients although confirmation of this would require a much
larger study. Notwithstanding the distinct differences in the
pathogenesis of these disorders, endothelial dysfunction is impli-
cated in the aetiology and progression of both these INOCA
endotypes.8,9,28 Treatment with drugs that improve endothelial
function and/or coronary blood flow have plausible symptomatic
and physiological benefits to patients with either of these
disorders.32
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Figure 4 Cumulative concentration-response curves to con-
strictor agonists. (A) Increased maximum vasoconstriction to endo-
thelin-1 in both microvascular angina subjects (blue circle,
endothelin-1 Emax 121%, n = 54; P = 0.03) and vasospastic angina
subjects (red triangle, endothelin-1 Emax 125%, n = 11; P = 0.02) vs.
control subjects (—white circle, endothelin-1 Emax 100%, n = 9; P
= 0.02). No difference in endothelin-1 Emax between microvascular
angina and vasospastic angina subjects (P = 0.397). Comparison of
CCRC fit, P < 0.001. (B) Cumulative concentration-response curves
to thromboxane analogue, U46619, in both microvascular angina
subjects (blue circle, U46619 Emax 143%, n = 54; P = 0.01) and vaso-
spastic angina subjects (red triangle, Emax 141%, n = 10; P = 0.04) vs.
control subjects (—white circle, endothelin-1 Emax 109%, n = 11).
No difference in Emax between microvascular angina and vasospastic
angina subjects (P = 0.932). Comparison of CCRC fit, P < 0.001.
Each measure represents mean ± 95% confidence intervals for
mean in shaded contours from CCRC best-fit.
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Mechanisms underlying endothelial
dysfunction and implications for
clinicians
Our work provides new insights into the presence and mechanisms
of systemic arteriolar dysfunction. The small arteries studied in vitro
were from a different vascular bed from those implicated in the
pathogenesis of coronary microvascular dysfunction. The cross-
sectional study design limits understanding of the natural history and
causality, and concomitant cardiovascular treatment is a potential
confounder. As such, our findings are associative but the structural
and functional changes that occur in human subcutaneous small
arteries in response to vascular risk factors, such as diabetes mellitus
and hypertension, have prognostic relevance33 and may be mirrored
in other circulatory beds (e.g. heart and brain).26 Future studies
should investigate microvascular structure/function relationships (e.g.
media: lumen ratio using pressure myography) due to the known
prognostic utility of this measurement.34
We did not measure nitric oxide (NO) and it is possible that bio-
available NO was not deficient, rather the mechanisms of vascular
dysfunction occurred in the vascular smooth muscle cells (VSMCs). It
is known that high doses of ACh provoke constriction via direct ac-
tion on vascular smooth muscle muscarinic receptors in the coronary
circulation. However, this effect does not occur in human small per-
ipheral arterioles.10,35 Modulation studies in human small peripheral
arterioles using exogenous NO donor (SNP) or a hyperpolarizing
agent (pinacidil) including measurements of endothelial nitric oxide
synthase (eNOS) support endothelial dysfunction as the
primary cause of failure to relax to ACh.36 In our study, we observed
appropriate in vitro vasorelaxation in response to the NO donor,
SNP, consistent with normal responses to exogenous NO. The
SNP-mediated effects are independent of NO derived from eNOS
activation and accordingly have been considered as endothelial-
independent vasorelaxation.37
Our results contrast with a study of forearm blood flow (FBF) that
reported preserved ACh mediated relaxation in patients with
Syndrome X (a historical term for angina with primary coronary
microvascular dysfunction—one endotype of INOCA).38
Additionally, the forearm constrictor response to ET-1 was reduced
in patients vs. controls possibly implicating ETA receptor down-
regulation in response to elevated ET-1 levels. Differences between
in vitro and in vivo studies of human endothelial function are well
recognized.39 Disparities between FBF and isolated resistance
arteries may reflect physiological variations between vessels of differ-
ing circulatory origin; gluteal biopsies provide solely subcutaneous re-
sistance arteries, whereas FBF occurs through larger muscular
arteries flow with less significant resistance to flow from resistance
arteries.
Putative mechanisms of increased
peripheral vasoconstriction
Our research findings stimulate the provocative concept that MVA
and VSA associate with a generalized susceptibility to vasoconstrictor
stimuli. We found enhanced contractile responses to both ET-1 and
U46619 in small resistance arteries from patients. This finding may be
due to endothelial dysfunction contributing towards an imbalance
of bioavailable constrictor factors (ET-1, thromboxane A2, reactive
oxygen species, and prostaglandin) which predominate over endo-
thelium derived relaxing factors (nitric oxide (NO), prostacyclin (
PGI2) and endothelium derived relaxing factor (EDRF)). We
recognize the potential for concomitant epicardial vasospasm in
patients with coronary microvascular dysfunction and the potential
for exaggerated microvascular constriction in patients with VSA.40
Take home ﬁgure Systemic microvascular dysfunction in microvascular and vasospastic angina.
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Removing the endothelium (denuding) in the arterioles of subjects
from both groups would have allowed further insights into the mech-
anism of increased contractility.
Abnormalities vascular at VSMC level with pathological constrictor
response to ACh in the smooth muscle is another alternative mech-
anism (also associated with oxidative stress). Vascular smooth muscle
cells contain several sources of reactive oxygen species that mediate
many pathophysiological processes such as growth, migration, apop-
tosis, and secretion of inflammatory cytokines.41 Indeed, hypercon-
traction of VSMCs is the proposed mechanism of epicardial VSA.31
Many patients with epicardial vasospasm are likely to have coronary
microvascular dysfunction and exaggerated microvascular constric-
tion as a cause of ischaemia. It is certainly plausible that generalized
vascular smooth muscle responsiveness was enhanced and testing
other constrictor agonists (e.g. noradrenaline) would have been in-
formative. Our patients have coronary microvascular and/or epicar-
dial propensity to vasospasm which can lead to ischaemia or even
myocardial infarction.42 It is a plausible concept that vascular diseases
including migraine, Raynaud’s and MVA are linked by a propensity to
vasoconstriction with endothelial dysfunction.43,44
Limitations
As with all case–control studies, the selection of a true ‘reference
control’ group is a potential limitation. Within the constraints of any
matching criteria, we approached consecutive patients with negative
testing of coronary function with similar exposure to risk factors and
confounders that were representative of the population at risk.
Nevertheless, assignment of participants to the control group in this
way may have introduced unmeasured confounding bias.
The diagnosis of MVA in our population followed established
guidelines, however, the underlying pathophysiology is likely to differ
between individual patients reflecting ‘real world’ practice. We rec-
ognise other even more in depth endotypes, such as the 0coronary
slow flow phenomenon0 proposed by Tambe et al.45 and more re-
cently by Beltrame’s group.46 These patients characteristically have
isolated increase in microvascular resistance at rest but preserved
CFR. Another subgroup is ‘microvascular vasospasm’ proposed by
Mohri et al.47 While respecting these distinct subgroups, our classifi-
cation dichotomises patients with isolated epicardial vasospasm (VSA
group) from patients with microvascular dysfunction ‘MVA group’,
and importantly, these are defined to align with contemporary
COVADIS criteria.27 We hope future studies extend our research
unravelling the pathophysiology of distinct endotypes within cohorts
with INOCA enabling a precision medicine approach.30
Despite the normalization process that serves to standardize
each experiment, in vitro myography does not fully replicate
physiological conditions in vivo. Considering the primary outcome
of the maximum vasorelaxation response to ACh, we averaged
the response of arterioles in order to increase accuracy and aver-
age within subject variation of microvascular function. Indeed, the
same approach is established for other physiological measure-
ments, including guidewire-based coronary thermodilution for
measurement of coronary microvascular resistance.16,17
Additionally, vessel dissection, processing, and removal of perivas-
cular fat may alter vascular function. Perivascular fat plays an im-
portant neurohormonal function which modifies vascular
reactivity.48 Despite an experienced team of scientists, we could
not extract viable vessels from all of the biopsies and a minority of
samples provided only one or two vessels. This experience is typ-
ical in isometric tension recordings in human blood vessels.
Therefore, a complete set of pharmacological experiments
was not feasible in in all subjects (Table 3). We have described one
of the largest series of myography experiments in a single study,
and the largest to date in patients with INOCA. Nonetheless, the
sample size is a potential limitation of our study inherent to the
technically demanding procedure of gluteal fat biopsy and wire
myograph protocol.
Future directions
Recent trials have increased physician awareness of stable coronary
syndromes beyond fixed luminal obstruction; half of patients may
have ongoing angina despite technically successful percutaneous cor-
onary intervention.49 The relationship between CAD, ischaemia, and
angina is not straight forward and functional coronary disorders are
relevant. Our work supports the call from a recent White Paper for
more research into the diagnosis and management of INOCA.1
Endothelin-1 is a potent endogenous vasoconstrictor peptide. In
this study, ET-1 was 50 times more potent than the thromboxane
A2 analogue U46619. The increased constriction to ET-1 observed in
the present study raises the question about whether interventions
which reduce the effects of this peptide may, therefore, be useful in
the treatment of such patients. An appreciable component of the
coronary smooth muscle contractile response to ET-1 signalling
mechanism is calcium antagonist-resistant.50 This suggests a role for
selective ET receptor antagonists in the treatment of patients with
INOCA. Further studies are required to assess whether selective ET-
1 receptor modulation may be helpful in these patients.
In conclusion, we have identified peripheral endothelial dysfunc-
tion and enhanced vasoconstriction in MSA and VSA. These proc-
esses may involve ET-1. Small vessel damage in the heart may be part
of a widespread phenomenon with INOCA patients at risk of other
small vessel diseases. Overall, further research is required but this
study reminds us to think of angina as a cardiac symptom of a system-
ic disease where treatment of the entire cardiovascular system
(including basic lifestyle measures) should be encouraged.
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